在HIV-1感染、治疗经验丰富的受试者中,多替格拉韦加达鲁那韦的持久性增强了其作为挽救或简化挽救方案的效果。

Q2 Medicine
Amedeo F Capetti, Giuseppe V De Socio, Maria V Cossu, Gaetana Sterrantino, Giovanni Cenderello, Annamaria Cattelan, Gian M Baldin, Alessandro Soria, Niccolò Riccardi, Fosca P Niero, Benedetto M Celesia, Giorgio Barbarini, Stefano Rusconi, Giuliano Rizzardini
{"title":"在HIV-1感染、治疗经验丰富的受试者中,多替格拉韦加达鲁那韦的持久性增强了其作为挽救或简化挽救方案的效果。","authors":"Amedeo F Capetti,&nbsp;Giuseppe V De Socio,&nbsp;Maria V Cossu,&nbsp;Gaetana Sterrantino,&nbsp;Giovanni Cenderello,&nbsp;Annamaria Cattelan,&nbsp;Gian M Baldin,&nbsp;Alessandro Soria,&nbsp;Niccolò Riccardi,&nbsp;Fosca P Niero,&nbsp;Benedetto M Celesia,&nbsp;Giorgio Barbarini,&nbsp;Stefano Rusconi,&nbsp;Giuliano Rizzardini","doi":"10.1080/15284336.2018.1550290","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance.</p><p><strong>Objective: </strong>Aim of the present study is to assess the long term (96-week) safety and efficacy of DTG + bDRV in a of multidrug-experienced HIV-1 infected patients, simplifying or building rescue regimens.</p><p><strong>Methods: </strong>All HIV-1-infected subjects from eleven Italian centers switched to DTG + bDRV between March 2014 and September 2015 were included and followed for minimum 96 weeks.</p><p><strong>Results: </strong>The cohort comprises 130 subjects, switched from 42 different, complex or at least twice-daily regimens, mainly for simplification (44.6%), viral failure (30.0%) or toxicity (16.6%). At baseline 118 had documented resistance to 1-5 antiretroviral classes and 12 lacked genotypic results either for historical reasons or for problems with primer annealing; 52 (40%) had uncontrolled viral replication, three above 500.000 copies/mL. At week 96 two showed ≥50 HIV-1 RNA copies/mL, 23 had 1-49 copies/mL and 101 had no virus detected. The proportion of subjects presenting abnormal values at baseline significantly decreased for serum glucose, creatinine, AST, total cholesterol and triglycerides.</p><p><strong>Conclusions: </strong>These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.</p>","PeriodicalId":13216,"journal":{"name":"HIV Clinical Trials","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2018-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/15284336.2018.1550290","citationCount":"12","resultStr":"{\"title\":\"Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.\",\"authors\":\"Amedeo F Capetti,&nbsp;Giuseppe V De Socio,&nbsp;Maria V Cossu,&nbsp;Gaetana Sterrantino,&nbsp;Giovanni Cenderello,&nbsp;Annamaria Cattelan,&nbsp;Gian M Baldin,&nbsp;Alessandro Soria,&nbsp;Niccolò Riccardi,&nbsp;Fosca P Niero,&nbsp;Benedetto M Celesia,&nbsp;Giorgio Barbarini,&nbsp;Stefano Rusconi,&nbsp;Giuliano Rizzardini\",\"doi\":\"10.1080/15284336.2018.1550290\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance.</p><p><strong>Objective: </strong>Aim of the present study is to assess the long term (96-week) safety and efficacy of DTG + bDRV in a of multidrug-experienced HIV-1 infected patients, simplifying or building rescue regimens.</p><p><strong>Methods: </strong>All HIV-1-infected subjects from eleven Italian centers switched to DTG + bDRV between March 2014 and September 2015 were included and followed for minimum 96 weeks.</p><p><strong>Results: </strong>The cohort comprises 130 subjects, switched from 42 different, complex or at least twice-daily regimens, mainly for simplification (44.6%), viral failure (30.0%) or toxicity (16.6%). At baseline 118 had documented resistance to 1-5 antiretroviral classes and 12 lacked genotypic results either for historical reasons or for problems with primer annealing; 52 (40%) had uncontrolled viral replication, three above 500.000 copies/mL. At week 96 two showed ≥50 HIV-1 RNA copies/mL, 23 had 1-49 copies/mL and 101 had no virus detected. The proportion of subjects presenting abnormal values at baseline significantly decreased for serum glucose, creatinine, AST, total cholesterol and triglycerides.</p><p><strong>Conclusions: </strong>These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.</p>\",\"PeriodicalId\":13216,\"journal\":{\"name\":\"HIV Clinical Trials\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/15284336.2018.1550290\",\"citationCount\":\"12\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Clinical Trials\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/15284336.2018.1550290\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Clinical Trials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/15284336.2018.1550290","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 12

摘要

背景:Dolutegravir (DTG) +增强的darunavir (bDRV)是一种紧凑,粘附友好的挽救方案,具有最高的HIV-1耐药遗传屏障。目的:本研究的目的是评估DTG + bDRV在多种药物经历的HIV-1感染患者的长期(96周)安全性和有效性,简化或建立救援方案。方法:纳入2014年3月至2015年9月期间从11个意大利中心切换到DTG + bDRV的所有hiv -1感染受试者,随访至少96周。结果:该队列包括130名受试者,从42种不同的、复杂的或至少每天两次的方案中切换而来,主要是简化(44.6%)、病毒失败(30.0%)或毒性(16.6%)。基线时,118人对1-5种抗逆转录病毒耐药,12人由于历史原因或引物退火问题缺乏基因型结果;52例(40%)有不受控制的病毒复制,3例超过500.000拷贝/mL。96周时,2例HIV-1 RNA拷贝数≥50份/mL, 23例1-49份/mL, 101例未检出病毒。血清葡萄糖、肌酐、AST、总胆固醇和甘油三酯在基线时出现异常值的受试者比例显著降低。结论:这些长期数据证实了由bDRV + DTG组成的双药方案在HIV-1感染抢救环境中的可靠性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects.

Background: Dolutegravir (DTG) plus boosted darunavir (bDRV) is a compact, adherence-friendly salvage regimen with the highest genetic barrier to HIV-1 resistance.

Objective: Aim of the present study is to assess the long term (96-week) safety and efficacy of DTG + bDRV in a of multidrug-experienced HIV-1 infected patients, simplifying or building rescue regimens.

Methods: All HIV-1-infected subjects from eleven Italian centers switched to DTG + bDRV between March 2014 and September 2015 were included and followed for minimum 96 weeks.

Results: The cohort comprises 130 subjects, switched from 42 different, complex or at least twice-daily regimens, mainly for simplification (44.6%), viral failure (30.0%) or toxicity (16.6%). At baseline 118 had documented resistance to 1-5 antiretroviral classes and 12 lacked genotypic results either for historical reasons or for problems with primer annealing; 52 (40%) had uncontrolled viral replication, three above 500.000 copies/mL. At week 96 two showed ≥50 HIV-1 RNA copies/mL, 23 had 1-49 copies/mL and 101 had no virus detected. The proportion of subjects presenting abnormal values at baseline significantly decreased for serum glucose, creatinine, AST, total cholesterol and triglycerides.

Conclusions: These long-term data confirm the reliability of the two-drug regimen consisting of bDRV plus DTG in salvage settings in HIV-1 infection.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
HIV Clinical Trials
HIV Clinical Trials 医学-传染病学
CiteScore
1.76
自引率
0.00%
发文量
0
审稿时长
>12 weeks
期刊介绍: HIV Clinical Trials is devoted exclusively to presenting information on the latest developments in HIV/AIDS clinical research. This journal enables readers to obtain the most up-to-date, innovative research from around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信